SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 5.1% Beneficial Ownership in VOR Biopharma Inc.
Beneficial Ownership Report
FMR LLC and its principal, Abigail P. Johnson, have filed an amended Schedule 13G, reporting a beneficial ownership of 5.1% of VOR Biopharma Inc.'s common stock as of March 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 6,422,496 shares of VOR Biopharma Inc.'s common stock.
- This ownership represents 5.1% of the total outstanding common stock of VOR Biopharma Inc.
- FMR LLC holds sole voting power over 6,416,012 shares and sole dispositive power over 6,422,496 shares.
- Abigail P. Johnson, as a Director, Chairman, and CEO of FMR LLC, is deemed to have sole dispositive power over 6,422,496 shares.
- The filing is an Amendment No. 5 to Schedule 13G, indicating a change from previous ownership disclosures.
- The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of VOR Biopharma Inc.
Sentiment
Score: 7
Explanation: The filing indicates a significant beneficial ownership stake by a major investment firm, FMR LLC, and its principal, Abigail P. Johnson, in VOR Biopharma Inc., which can be viewed as a vote of confidence. However, it is purely an ownership disclosure and does not provide operational or financial performance details.
Positives
- The disclosure of a 5.1% beneficial ownership by a prominent investment firm like FMR LLC and its principal, Abigail P. Johnson, can be interpreted as a vote of confidence in VOR Biopharma Inc.'s prospects.
- The statement that shares were acquired and are held in the ordinary course of business suggests a long-term investment perspective rather than an activist intent.
Risks
- The document does not contain specific risks related to VOR Biopharma Inc.'s operations or financial health, as it is an ownership disclosure filing.
Future Outlook
This Schedule 13G filing is an ownership disclosure and does not contain any forward-looking statements or guidance regarding VOR Biopharma Inc.'s future performance or strategic outlook.
Industry Context
This filing reflects a significant institutional investment in VOR Biopharma Inc., a company likely operating in the biopharmaceutical sector, by a major asset management firm. Such disclosures are common and indicate ongoing investor interest in the sector, which is often characterized by high growth potential and significant R&D investment.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Internal Governance Structure Disclosure | The document details the internal governance structure of FMR LLC, noting that members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares (49% voting power) and have a shareholders' voting agreement, which may deem them to form a controlling group with respect to FMR LLC under the Investment Company Act of 1940. This relates to the reporting entity, FMR LLC, not VOR Biopharma Inc.'s corporate governance. | N/A | Provides transparency into the control structure of the reporting entity (FMR LLC) but has no direct impact on VOR Biopharma Inc.'s corporate governance. |
Related Party Transactions
- The filing details the relationship between FMR LLC and Abigail P. Johnson, stating that Abigail P. Johnson is a Director, Chairman, and CEO of FMR LLC, and that Johnson family members are predominant owners of FMR LLC's voting shares. This establishes the basis for Abigail P. Johnson's beneficial ownership reporting alongside FMR LLC.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional holder like FMR LLC can influence investor perception and potentially market sentiment for VOR Biopharma Inc.'s stock.
Key Dates
| Date | Description |
|---|---|
| 2023-01-03 | Effective date of Power of Attorney for FMR LLC and its direct and indirect subsidiaries. |
| 2023-01-26 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting period end date). |
| 2025-05-09 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
VOR Biopharma Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biopharma, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.